Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs Constellation CEO Jigar Raythatha will present at the J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019, at 4PM PST/7PM ESTThe presentation will include updated results from the first...

Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of Myelofibrosis - Recently Expanded and Enhanced MANIFEST Phase 2 Trial Ongoing with Proof of Concept Data Expected Mid-2019 CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals,...

Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis – Amends second-line trial design to stratify for transfusion dependence based on positive preliminary data – – Expands study to include an additional arm evaluating CPI-0610 as first-line therapy in...